Literature DB >> 9433491

Maspin. A tumor suppressing serpin.

R Sager1, S Sheng, P Pemberton, M J Hendrix.   

Abstract

Maspin, a serpin found in mammary epithelial cells, has been shown to have tumor suppressor activity. The gene is expressed in normal human mammary epithelial cells but down-regulated in invasive breast carcinomas. Similar patterns of expression at the RNA and protein levels are seen by Northern analysis with cells grown in culture and by immunostaining of tissues. Biological assays of invasion by tumor cells through Matrigel membranes and of motility have shown that recombinant maspin inhibits both processes, and that its inhibitory action is totally lost by a single cleavage at the reaction center. Tumor transfectants expressing maspin are inhibited in growth and metastasis in nude mice. Maspin is located in the cell membrane and extracellular matrix, and does not behave as a classical inhibitory serpin against any known target protease. Its mode of action is presently unknown.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9433491

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  12 in total

1.  AZU-1: a candidate breast tumor suppressor and biomarker for tumor progression.

Authors:  H M Chen; K L Schmeichel; I S Mian; S Lelièvre; O W Petersen; M J Bissell
Journal:  Mol Biol Cell       Date:  2000-04       Impact factor: 4.138

2.  Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum.

Authors:  John B Welsh; Lisa M Sapinoso; Suzanne G Kern; David A Brown; Tao Liu; Asne R Bauskin; Robyn L Ward; Nicholas J Hawkins; David I Quinn; Pamela J Russell; Robert L Sutherland; Samuel N Breit; Christopher A Moskaluk; Henry F Frierson; Garret M Hampton
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-06       Impact factor: 11.205

3.  Characterisation of PAUSE-1, a powerful silencer in the human plasminogen activator inhibitor type 2 gene promoter.

Authors:  S M Ogbourne; T M Antalis
Journal:  Nucleic Acids Res       Date:  2001-10-01       Impact factor: 16.971

4.  Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs).

Authors:  Adriana S Beltran; Pilar Blancafort
Journal:  Epigenetics       Date:  2011-02-01       Impact factor: 4.528

5.  Expression of CD34 and maspin in ameloblastoma from a West African subpopulation.

Authors:  S E Udeabor; A O Adisa; B Kolude; M Barbeck; C J Kirkpatrick; R A Sader; S Ghanaati
Journal:  Tumour Biol       Date:  2014-05-09

6.  A five-variable signature predicts radioresistance and prognosis in nasopharyngeal carcinoma patients receiving radical radiotherapy.

Authors:  Hong-Mei Yi; Hong Yi; Jin-Feng Zhu; Ta Xiao; Shan-Shan Lu; Yong-Jun Guan; Zhi-Qiang Xiao
Journal:  Tumour Biol       Date:  2015-09-27

7.  Gene expression changes during HPV-mediated carcinogenesis: a comparison between an in vitro cell model and cervical cancer.

Authors:  Fang Wan; Xijiang Miao; Iram Quraishi; Valerie Kennedy; Kim E Creek; Lucia Pirisi
Journal:  Int J Cancer       Date:  2008-07-01       Impact factor: 7.396

8.  Highly expressed histone deacetylase 5 promotes the growth of hepatocellular carcinoma cells by inhibiting the TAp63-maspin pathway.

Authors:  Hongqian Gu; Zejun Fang; Xiang Cai; Rui Song; Min Lin; Jiangwei Ye; Xiaokun Ding; Qinjian Ke; Haihong Chen; Chaoju Gong; Ming Ye
Journal:  Am J Cancer Res       Date:  2018-03-01       Impact factor: 6.166

9.  Human Chondrosarcoma Cells Acquire an Epithelial-Like Gene Expression Pattern via an Epigenetic Switch: Evidence for Mesenchymal-Epithelial Transition during Sarcomagenesis.

Authors:  Matthew P Fitzgerald; Francoise Gourronc; Melissa L T Teoh; Matthew J Provenzano; Adam J Case; James A Martin; Frederick E Domann
Journal:  Sarcoma       Date:  2011-03-17

10.  Suppression of breast tumor growth and metastasis by an engineered transcription factor.

Authors:  Adriana S Beltran; Angela Russo; Haydee Lara; Cheng Fan; Paul M Lizardi; Pilar Blancafort
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.